Prulifloxacin as a trigger of myasthenia gravis.
Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG). We present a case of MG following a treatment with prulifloxacin, a new broad-spectrum oral fluoroquinolone. Fluoroquinolones of any generation may interfere with neuromuscular transmission and should be avoided in patients with MG.
Rossi
Marco
M
Department of Pharmacology Giorgio Segre, University of Siena, Siena, Italy. marcorss@alice.it
Lusini
Gaia
G
Biasella
Alessia
A
Mazzocchio
Riccardo
R
D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003556:Cystitis / Q000188:drug therapy; D004148:Dioxolanes / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009157:Myasthenia Gravis / Q000139:chemically induced*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D004148:Dioxolanes; D024841:Fluoroquinolones; D010879:Piperazines; C074191:prulifloxacin